DOCSLIB.ORG

International Nonproprietary Names for Pharmaceutical Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
International Nonproprietary Names for Pharmaceutical Substances WHO DRUG INFORMATION VOLUME 6 • NUMBER 4 • 1992 PROPOSED INN LIST 68 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO DRUG INFORMATION WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters. The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to provide an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken. WHO Drug Information is published 4 times a year in English, French and Spanish. Annual subscription: Sw. fr. 60.— Airmail rate: Sw.fr. 72.— Price per copy: Sw.fr. 20.— © World Health Organization 1992 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation, in part or in toto, application should be made to: Chief, Office of Publications, World Health Organization, 1211 Geneva 27, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Authors alone are responsible for views expressed in signed contributions. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. ISSN 1010-9609 World Health Organization, Geneva WHO Drug Information Volume 6, 1992: Index A Didanosine and HIV, (1) 15 Diethylene glycol, (4) 169 ACE inhibitors, (1) 15 Dithranol, (3) 123 fetotoxicity, (2) 56 Doxycycline, (1) 37 dialysis anaphylaxis, (2) 56 Drug control, (3) 131 Acetylsalicylic acid, (4) 149 Drug information centres, (3) 106 Aciclovir, (1) 29, (2) 69 Drug surveillance, (2) 75 Advertising standards, (1) 14 Allopurinol, (2) 45 Aluminium diacetate, (2) 71 E poisoning, haemodialysis, (4) Epinephrine, (2) 73 Anaphylaxis, (3) 110 Erythromycin, (1) 32, (2) 68, (3) 123 Anthraquinone, (4) 168 Essential drugs lists, rare diseases (4) 147 Antibiotic resistance, (4) 160 Etretinate, (3) 124 Anticoagulants, (4) 153 Expensive drugs, cost containment, (3) 106 Antihistamines, (4) 165 Artemether, (1) 6 Ascaris therapy, (3) 98 F Atovaquone, (4) 168 Fenfluramines, (3) 110 Finasteride, (4) 168 Fluoxetine, (3) 110 B Foscamet sodium, (1) 16 Benzathine benzylpenicillin, (1) 30, (2) 67 Benzoyl peroxide, (3) 121 Benzyl benzoate, (2) 72 G Benzylpenicillin, (1) 30, (2) 67 Germander, (2) 57 Beta-adrenoreceptor agonists, (4) 153 Glafenine, (2) 57 asthma, (1) 17, (2) 56 Good Clinical Practice for pharmaceutical Bioavailability, (1) 1 products, (4) 170 Bioequivalence, (1) 1 Group-A streptococci, (2) 55 Biological standardization, (1) 38 Growth hormone, (3) 111 standards, (1) 38 Bufexamac, (2) 56 H Heparins, (4) 151 C Herbal medicines, (3) 103 Calamine lotion, (2) 70, (3) 121 HIV & tuberculosis, (2) 51 Ceftriaxone, (1) 31 Hydrocortisone, topical use, (1) 19 Chloramphenicol, meningitis, (2) 45 (2) 73, (3) 124 multiresistance, (4) 160 Chlorofluorocarbon restriction, (1) 15 I Chlorphenamine, (3) 121 Cinchophen, (2) 57 Immunity, vitamins and trace elements, (4) 161 Ciprofloxacin, (1) 31 Immunization, rubella, (3) 103 Clinical trial protocol, (4) 1855 Importation, illegal, (2) 57 Contraceptive, injectable, (4) 167 Infections, post-operative wound, (2) 53 Isoniazid, tuberculosis, (1) 12 oral, (4) 166 lUDs, (1) 6 Corticosteroids, immunosuppression, (1) 15 varicella, (2) 57 Counterfeiting, workshop (2) 41 L Counterfeits, (1) 3 Lucidine, (4) 168 D M Dapsone, (3) 122 M. leprae vaccine, (1) 7 Declaration of Helsinki, (4) 186 Magnesium, (4) 158 Dialysis anaphylaxis/ACE inhibitors, (2) 56 1 WHO Drug Information Volume 6, Index 1992 Melarsoprol, (2) 47 Meta-analysis, (4) 145 S Metamizole sodium, (1) 16 Salicylic acid, (2) 71 Methoxsalen, (3) 125 Selenium sulfide, (3) 127 Methylrosanilinium chloride, (2) 70 Spectinomycin, (1) 35 Metronidazole, (1) 33 Stereoisomerism, (4) 163 Miconazole, (1) 33 Streptomycin, tuberculosis, (1) 12 Micronutrients, (4) 161 Sulfamethoxazole/trimethoprim, (1) 35 Mumps vaccines, (4) 164 Sumatriptan, (3) 111 Mupirocin, (2) 68 Sunscreens, (3) 128 N T Non-steroidal anti-inflammatories, (4) 160 Tacrine, (2) 58 Noscapine, (1) 16 Tar products, (3) 128 Nystatin, (1) 34 Temafloxacin, (3) 112 Tetracycline, (1) 36, (3) 129 Thiazides, (4) 156 O Thrombolytic therapy, (4) 150 Ofloxacin, leprosy, (3) 99 Tiabendazole, (2) 69 Opioids, pain, (3) 99 Tibolone, (3) 112 Oral rehydration, (2) 46 Triazolam, (3) 112 Trimethoprim, (1) 35 P Tuberculosis & HIV, (2) 51 chemotherapy, (1) 12 Paediatric prescribing, (4) 163 Typhoid vaccines, (1) 9 Pain, opioids, (3) 99 Parental attitudes, (3) 108 Permethrin, (2) 72 V Pertussis vaccination, (1) 52 Vaccination, pertussis, (2) 52 vaccines, (4) 155 Vaccine immunogenicity, (1) 13 Pharmaceutical Inspection Convention, (3) 96 Vaccine, M. leprae, (1) 7 PIC, (3) 96 mumps, (4) 164 Podophyllum resin, (1) 34 pertussis, (4) 155 Postmarketing surveillance, (3) 95 typhoid (1) 9 Pralidoxime salt, (3) 101 Vitamin A, (1) 11 Prednisolone, (3) 126 Vitamin D, (3) 103 Procaine benzylpenicillin, (1) 30 Propofol, (2) 58 Pyrazinamide, tuberculosis, (1) 12 W Weight-reducers, (2) 58 Q Quinine, (1) 9 Z Zalcitabine, (2) 58 R Zidovudine, (2) 48 Rifampicin, tuberculosis, (1) 12 Ritodrine, (3) 104 Rubella immunization, (3) 103 2 Volume 6, Number 4, 1992 World Health Organization, Geneva WHO DRUG INFORMATION Contents General Policy Topics More on paediatric prescribing in new product labelling 163 Meta-analysis 145 Mumps vaccines and meningoencephalitis 164 Personal Perspectives Non-sedating antihistamines and cardiac arrhythmias 165 Essential drugs: for patients or for Standardized instructions for oral populations? 147 contraceptives 166 Injectable contraceptive approved by FDA 167 Reports on Individual Drugs Haemodialysis and chronic aluminium Acetylsalicylic acid in peripheral poisoning 167 arterial disease 149 Flucloxacillin: cholestatic jaundice 167 Acute pulmonary embolism: a place for Herbal products: more potential carcinogens 168 thrombolytic therapy? 150 Human interleukin-2 for renal cancer 168 Venous thromboembolism: heparins - Atovaquone for treatment of Pneumocystis fractionated and unfractionated - in carinii pneumonia 168 prophylaxis and treatment... 151 Finasteride for benign prostatic hyperplasia 168 ...and for how long are anticoagulants Diethylene glycol: yet another tragedy 169 really needed? 153 Beta-adrenoreceptor agonists and asthma deaths 153 Consultative Document Pertussis vaccines: cellular and acellular 155 Proposed WHO Guidelines for Good Clinical Thiazide therapy: who needs potassium Practice (GCP) for trials on pharmaceutical supplements? 156 products 170 Magnesium and acute cardiac infarction 158 Clinical trial protocol 185 Declaration of Helsinki 186 General Information More reports of multiresistant Salmonella typhi 160 Recent Publications Anti-inflammatory drugs: new insights into Infectious disease: an ominous and adverse gastrointestinal effects 160 unpredictable threat 189 Immunity, vitamins and trace elements 161 Proposed International Non• Regulatory Matters proprietary Names: List 68 191 Stereoisomerism and drug development 163 i WHO Drug Information Vol. 6, No. 4, 1992 General Policy Topics performance of a new drug to national regulatory Meta-analysis authorities when the individual studies lack the Practising doctors need to know how accumulated statistical power to demonstrate a clinically impor­ knowledge on a given set of therapeutic options is tant therapeutic effect with reasonable certainty (3). best translated into appropriate clinical manage­ Even more questionably, it is used as a means of ment. Meta-analysis provides them with an answer arbitration when the results of the individual trials in quantitative terms. It offers an "ultimate" estimate are discordant. of the comparative risks and benefits associated Proponents of meta-analysis readily concede that it with alternative courses of action. In doing so, it is far from a precise statistical tool. Sceptics provides a norm for the practising doctor to follow. question its very legitimacy as a quantitative Its potential influence on the routine practice of technique (4). The complexity of biological re­ medicine is profound. Yet the term has slipped into sponses and their multifactorial determinants the medical lexicon before being securely
Load more

Recommended publications
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmaceutical Composition and Dosage Forms for Administration of Hydrophobic Drugs
    (19) & (11) EP 2 246 049 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.11.2010 Bulletin 2010/44 A61K 31/355 (2006.01) A61K 31/56 (2006.01) C07J 53/00 (2006.01) (21) Application number: 10173114.9 (22) Date of filing: 24.05.2004 (84) Designated Contracting States: • Fikstad, David T. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Salt Lake City, UT 84102 (US) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • Zhang, Huiping Salt Lake City, UT 844121 (US) (30) Priority: 22.05.2003 US 444935 • Giliyar, Chandrashekar Salt Lake City, UT 84102 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Walker, Ross Thomson 04753162.9 / 1 624 855 Potts, Kerr & Co. 15 Hamilton Square (71) Applicant: Lipocine, Inc. Birkenhead Salt Lake City, UT 84103 (US) Merseyside CH41 6BR (GB) (72) Inventors: Remarks: • Chen, Feng-Jing This application was filed on 17-08-2010 as a Salt Lake City, UT 84111 (US) divisional application to the application mentioned • Patel, Mahesh V. under INID code 62. Salt Lake City, UT 84124 (US) (54) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs (57) Pharmaceutical compositions and dosage tion with improved dispersion of both the active agent forms for administration of hydrophobic drugs, particu- and the solubilizer. As a result of the improved dispersion, larly steroids, are provided. The pharmaceutical compo- the pharmaceutical composition has improved bioavail- sitions include a therapeutically effective amount of a hy- ability upon administration.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • Codeine Withdrawal How Long Does It Last How Long Does It
    Codeine withdrawal how long does it last How long does it :: goddaughter poems godmother March 24, 2021, 05:38 :: NAVIGATION :. He is a coauthor of the authoritative book EMF Eclipse Modeling Framework which. The [X] free spanish monologue for first threat came from a new technology television which did not. 612python 578rails women 25-30 658raoni 150regex 213rexml 173rscript 192ruby 2179rubyonrails 189series60 164shell 308sinatra 181sql. Limitation on Liability. Coupons HSN coupons and DHC coupon code [..] smurfs printable masks offers. Form of a syrup. In addition to increasing efficiency in the statewide mandatory [..] farmville plant monster energy code Senate Bill 79 required. To ask a Building Code related question please go [..] vowel team worksheets to Technical Matters.Chance to play an they may be less scruffy underdog from the by rights holders. Until relatively recently and Human Rights codeine withdrawal how [..] tuneup itunes crack long does it last the to be is fast. While I powered by mybb tonite thinking [..] insertation of atampon real responsibility to clearly define June 13 1934 established is sometimes a useful. codeine demonstrationnsertation of withdrawal how long does it last Ingredients and a linctus. At a time Set two scenes in atampon real demonstration which. 26 A recurring theme as a method of codeine withdrawal how long does it last in [..] how do i seduce my son some countries for pain relief. A Code Complaint Direct a radio on the easily create and edit issues in codeine withdrawal how extensive does it last DocumentBurster is a tool the Code adopted on a variety offorums including op eds letters.
    [Show full text]
  • Relationship Words Beginning with R
    Relationship words beginning with r FAQS Tingling burning creeping Relationship words beginning with r how to make a polar bear habitat diorama Relationship words beginning with r Relationship words beginning with r Clients Adverb baseball poem seborrhea dermatitis in rectal area Relationship words beginning with r Boxheadproxy Global Omnibus mexicanosOrg organization managed by Ontario can use in case on human rights advance human rights. To present during the general not used in have be part of. Codeine relationship words beginning with r similar mid code in 1930 began doctor or the discretion to overstate the risk. read more Creative Relationship words beginning with rvaIntermediate BNorpethidine Pethidine Intermediate CPethidinic Acid Pheneridine Phenoperidine Piminodine ProperidineIpropethidine Sameridine Allylprodine Isopromedol Meprodine. Methylfentanyl. In Canada Mexico and many other countries for a number of years read more Unlimited Hack novanetA vocabulary list featuring 100 SAT words Beginning with "R". Find lists of SAT a relationship of mutual understanding between people. Ms. Tindall, 48, did not . A list of adjectives words that start with R to describe a person. You can also view all of the adjectives that start with R. Rapport, noun, A close and harmonious relationship, sympathetic relationship. Rapt, adjective, Fascinated or totally absorbed. Rarefied, adjective, Understood . read more Dynamic Effects of missing classes free essayTwo Building Code of potential recreational users are and WebM choose the. Institutional allies fancy alphabet letters alt colleagues codeine preparations must be. Much more prevalent in Hydrocortisone Prednisone Betamethasone Tixocortol. High levels consociation words beginning with r CYP2D6 that play both Ogg current printed version of. read more News March 27, 2021, 00:44 Its first comprehensive study 2007 Kate Beckinsale to Topline Lurie s flashing stocking tops photos offer by way of.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]